Supporting An Oncology Company In A Treatment For A Rare Tumor

Explore the development and scale-up of a regulatory starting material (RSM) for two complex drug candidates. The program required rapid process development, optimization, and GMP scale-up to support clinical supply while meeting stringent quality and regulatory expectations.

The chemistry involved significant complexity, including pyrophoric reagents, chiral purification, and the generation of impurity standards and isomers to support analytical validation. These challenges were addressed through close cross-functional collaboration to ensure safety, robustness, and scientific rigor throughout.

An integrated development approach enabled streamlining of the synthetic route, improving efficiency ahead of scale-up. Advanced analytical support ensured strong method validation and precise impurity characterization, maintaining consistent product quality.

The process was successfully transitioned from laboratory development to kilogram-scale GMP manufacturing within two years, supporting clinical advancement and demonstrating the value of an integrated, end-to-end development strategy for complex molecules.